Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 4/20 | 0.57 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.57 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.50 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29566662 | 0.98 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4RET | |
| Hydrochloric Acid SCHEMBL23607806 | 0.98 | CHRNB4 (0.56) | CHRNB4CHRNA3CHRNB2CHRNA4RET | |
| Trifluoroacetic Acid SCHEMBL29631347 | 0.85 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNA4RET | |
| Trifluoroacetic Acid SCHEMBL23501141 | 0.85 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNA4RET | |
| SCHEMBL23744094 | 0.82 | CHRNB4 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL23744768 | 0.82 | CHRNB4 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL30345800 | 0.82 | CHRNB4 (0.39) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL22795652 | 0.81 | CHRNB4 (0.38) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL25812286 | 0.81 | SMPD3 (0.37) | CHRNB4CHRNA3CHRNB2CHRNA4 | |
| SCHEMBL22516883 | 0.80 | CHRNB4 (0.44) | CHRNB4CHRNA3CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163437-B | Substituted pyrazolo [1,5-a ] pyridine compounds as RET kinase inhibitors | 阿雷生物药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12129266-B2 | Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2024-10-29 | — | — | US | disclosed |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2024-02-29 | — | — | US | disclosed |
| CN-111285886-B | Substituted pyrazolo [1,5-a ] pyridine compounds, compositions comprising the same and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-3992197-A1 | NITROGEN-CONTAINING POLYCYCLIC FUSED RING COMPOUNDS, AND PHARMACEUTICAL COMPOSITION THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Applied Pharmaceutical Science, Inc. (CN) | 2022-05-04 | — | — | EP | disclosed |
| US-20220017539-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20220017539-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2022-01-20 | — | — | US | disclosed |
| US-20210379056-A1 | SUBSTITUTED PYRAZOLE FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | APPLIED PHARMACEUTICAL SCIENCE, INC. (CN) | 2021-12-09 | — | — | US | disclosed |
| EP-3878852-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2021-09-15 | — | — | EP | disclosed |
| EP-3523301-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2020-05-27 | — | — | EP | disclosed |
| WO-2020064009-A1 | SUBSTITUTED PYRAZOLE FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 北京志健金瑞生物医药科技有限公司 | 2020-04-02 | — | — | WO | disclosed |
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ELI LILLY AND COMPANY (US) | 2020-02-11 | — | — | US | disclosed |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2018071447-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180134702-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB4 1708/4885CHRNA3 1700/4885CHRNB2 2276/4885 |
| US-12129266-B2 | Substituted pyrazolo[1,5-a]pyridine compound, composition containing the same and use thereof | RET, ROR1, BRAF | CHRNB4 2758/4885CHRNA3 2634/4885CHRNB2 2802/4885 |
| US-10555944-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | CHRNB4 1708/4885CHRNA3 1700/4885CHRNB2 2276/4885 |
| US-20180133200-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB4 1708/4885CHRNA3 1700/4885CHRNB2 2276/4885 |
| US-20210379056-A1 | SUBSTITUTED PYRAZOLE FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | RET, ROR1, WEE1 | CHRNB4 2569/4885CHRNA3 2808/4885CHRNB2 2739/4885 |
| US-20220017539-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUND, COMPOSITION CONTAINING THE SAME AND USE THEREOF | RET, ROR1, BRAF | CHRNB4 2758/4885CHRNA3 2634/4885CHRNB2 2802/4885 |
| US-10172851-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, ROR1, BRAF | CHRNB4 1708/4885CHRNA3 1700/4885CHRNB2 2276/4885 |
| US-20180133213-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB4 1708/4885CHRNA3 1700/4885CHRNB2 2276/4885 |
| US-20240066029-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | CHRNB4 1708/4885CHRNA3 1700/4885CHRNB2 2276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.